Pfizer, Inc. – Company Overview
|Headquarters||235 East 42nd Street, New York City, New York, USA|
|CEO||Ian C. Read|
|Founders||Charles Pfizer and Charles Erhart|
|NYSE stock symbol||PFE|
|Revenues||$48,851 million USD (2015)|
|Net income||$6,960 million USD (2015)|
|Corporate contact number||1-212-733-2323|
|Contact information||A contact information form can be found here|
Pfizer, Inc. (NYSE: PFE) focuses on the marketing and development of pharmaceutical and consumer healthcare products. In terms of total revenue it is the world’s largest drugmaker.
Pfizer has marketed and discovered the following drugs (which have contributed to its recent success): Lipitor, Viagra, Zoloft, Zithromax, Norvasc, Diflucan, and Aricept.
The company was originally founded in 1849 under the name Charles Pfizer and Company by two German-American cousins; Charles Pfizer and Charles Erhart.
Pfizer experienced significant growth in the late 19th century thanks to its production of citric acid and an antiparasitic called santonin.
The company was involved in the mass production of the antibiotic penicillin during World War II. In fact, Pfizer was one of the main pharmaceutical companies to provide penicillin to injured troops on D-Day.
Over the years the company transformed into a research-based pharmaceutical company.
Pfizer conducts its business through four main operating segments – Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare.
The company has made a number of significant acquisitions, including:
- Warner-Lambert (in 2000)
- Pharmacia (in 2003)
- Wyeth (in 2009)
Pfizer spent $6.7 billion in 2013 on research and development R&D. It operates R&D facilities in: Kalamazoo (Michigan), Cambridge (Massachusetts), Groton (Connecticut), San Francisco (California), La Jolla (California), St. Louis (Missouri), Cambridge (United Kingdom), and Sandwich (United Kingdom).
Zoetis, Agouron Pharmaceuticals, Wyeth, G. D. Searle & Company, Parke-Davis, Warner Lambert, and Greenstone.
Pfizer, Inc. – Financial Results
|Key figures (in millions of USD)||2015*||2014*|
|Cost of sales||$9,648||$9,577|
|Income from continuing operations||$6,975||$9,119|
|Cash and cash equivalents at beginning of period||$3,343||$2,183|
|Cash and cash equivalents at end of period||$3,641||$3,343|
*For the years ended December 31, 2015 and 2014